Table 12.6a

Immunosuppression Use for Induction, 1997 to 2006

Recipients with Lung Transplants

  Year of Transplant
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Transplants 948 893 922 977 1,083 1,054 1,099 1,185 1,407 1,406
With Immunosuppression Info 931 885 895 950 1,065 1,030 1,088 1,163 1,364 1,366
Induction Drugs 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
ALG
Atgam/NRATG/NRATS 19.5% 13.9% 12.6% 11.9% 8.8% 6.4% 4.9% 5.4% 3.9% 5.9%
OKT3 2.5% 3.5% 3.4% 2.6% 1.0% 0.6% 1.1% 0.5% 1.0% 1.3%
Thymoglobulin 0.0% 0.0% 1.9% 6.0% 5.4% 8.3% 3.0% 3.7% 3.0% 4.0%
Zenapax 0.0% 4.9% 9.6% 14.6% 11.3% 13.9% 15.7% 14.7% 12.6% 15.7%
Simulect 0.0% 0.3% 3.2% 8.3% 12.8% 15.0% 19.6% 23.0% 18.2% 24.4%
Campath 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.9% 3.6% 5.2% 7.2%
No Induction Drugs Recorded 78.2% 77.5% 69.5% 56.9% 61.1% 56.1% 55.8% 49.9% 56.8% 42.8%


Source: OPTN/SRTR Data as of May 1, 2007.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.